Human GDF-15 ELISA Kit
$350.00 – $450.00
Sample Type | Serum, plasma, cell culture supernatant, and other biological samples |
---|---|
Sample Volume | Serum, plasma: 10 μL;cell culture supernatant: 100 μL |
Sensitivity | 1.24 pg/mL |
Range | 15.63 pg/mL – 1000 pg/mL |
Assay Time | 3.5 h |
Recovery | 79% – 115% |
Average Recovery | 0.97 |
Intra Precision | 6.0% – 6.7% |
Inter-Precision | 3.3% – 5.9% |
Platform | ELISA |
Plate | Detachable 96-well plate |
Size | 96T/48T |
Storage | If the reagent kit is unopened, it should be stored at 4℃. However, if it has been opened, the standard solution should be stored at -20℃, while the other components should be stored at 4℃. |
Delivery | 4℃ blue ice transportation |
Components | 96-well polystyrene enzyme-linked immunosorbent assay (ELISA) plate coated with anti-Human GDF-15 monoclonal antibody Human GDF-15 freeze-dried standard GDF-15 detect Antibody HRP-labeled streptavidin Assay Buffer(10×) Substrate TMB Stop Solution Washing Buffer(20×) Sealing Film |
Assay Principle | This kit utilizes the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection technique.Specific anti-human GDF-15 antibodies are precoated on a high-affinity ELISA plate. Standard samples, test samples, and biotinylated detection antibodies are added to the wells of the ELISA plate. After incubation, GDF-15 present in the samples binds to the solid-phase antibodies and the detection antibodies. After washing to remove unbound substances, streptavidin-HRP labeled with horseradish peroxidase is added. After washing, a colorimetric substrate, TMB, is added and the plate is incubated in the dark for color development. The intensity of the color reaction is directly proportional to the concentration of GDF-15 in the samples.A stop solution is added to terminate the reaction, and the absorbance value is measured at a wavelength of 450 nm (with a reference wavelength range of 570-630 nm). |
Targets
GDF15
23.5
Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers
Nature Cancer
4
Exploration of treatment strategies and susceptibility gene of postoperative nausea and vomiting in breast cancer patients: a randomised controlled trial
Breast Cancer